Galcanezumab Prefilled Syringe + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vestibular Migraine
Conditions
Vestibular Migraine
Trial Timeline
Sep 18, 2020 → Sep 29, 2023
NCT ID
NCT04417361About Galcanezumab Prefilled Syringe + Placebo
Galcanezumab Prefilled Syringe + Placebo is a phase 2 stage product being developed by Eli Lilly for Vestibular Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT04417361. Target conditions include Vestibular Migraine.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04417361 | Phase 2 | Completed |
Competing Products
2 competing products in Vestibular Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nilotinib | Novartis | Phase 2 | 52 |
| Endostatin | Tiantan Bio | Phase 2 | 49 |